Researchers at Colorado State University, in collaboration with Creighton University, have developed patented compounds to treat non-tuberculous mycobacterial (NTM) lung infections. These drugs are designed to specifically target the bacteria causing pulmonary NTM, including highly resistant strains. Early studies suggest these compounds could offer a novel approach where existing antibiotics often fail. Their narrow-spectrum action may reduce side effects compared to broad-spectrum treatments.
NTM infections of the lungs are increasing worldwide, particularly in patients with structural lung diseases such as cystic fibrosis (CF), chronic obstructive pulmonary disease, and non-CF bronchiectasis. Rapidly growing NTM species, especially those from the Mycobacterium abscessus group (MABS), cause severe, often life-threatening diseases. Current therapies have high failure rates, prolonged treatment times, and limited success, particularly for MABS. New treatments that are both effective and selective against these pathogens are urgently needed.
This technology consists of indole-2-carboxamide compounds that selectively target NTM species, including multidrug-resistant strains of MABS and the Mycobacterium avium complex (MAC). Preclinical studies in animal models demonstrate that these compounds can effectively inhibit infection by intrinsically drug-resistant NTM. Unlike current antibiotic therapies, which often require prolonged intravenous and inhaled regimens and carry significant side effects, these compounds offer a more focused approach with potential for oral delivery, improved efficacy and tolerability.
The compounds’ specificity for mycobacteria could reduce collateral damage to beneficial bacteria and minimize adverse effects associated with broad-spectrum antibiotics. By addressing pathogens with high rates of drug resistance, these indole-based therapeutics provide a promising option for patients who have limited treatment choices today.
Available for Exclusive Licensing
Mary C Jackson
Jeffrey North
Jessy McGowan
Jessy.McGowan@colostate.edu
970-491-7100